Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HMPL-453 with Itraconazole and Rifampicin in Healthy Subjects
NCT07697157Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of fanregratinib in solid tumor (2 arms), sponsored by HUTCHMED. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration at 25 days, Area Under the Curve from Time Zero to Infinity at 25 days and 1 more. Started Mar 2025; status: completed.
02
Drugs
fanregratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07697157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697157.